Trials / Unknown
UnknownNCT05446688
A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma
A Phase 2, Multicenter, Non-Randomized, Open-Label, Single-Arm Study to Evaluate the Preliminary Efficacy and Safety of 6MW3211 in Patients With Relapsed or Refractory Lymphoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single arm, non-randomized, open label phase 2 international, multicenter clinical trial to evaluate preliminary efficacy and safety in subjects with relapsed or refractory lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 6MW3211 | 6MW3211 injection, 45mg/kg, Q2W |
Timeline
- Start date
- 2022-09-01
- Primary completion
- 2024-03-01
- Completion
- 2024-09-01
- First posted
- 2022-07-07
- Last updated
- 2022-07-07
Source: ClinicalTrials.gov record NCT05446688. Inclusion in this directory is not an endorsement.